Ocular Therapeutix™ Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Ocular Therapeutix (OCUL) PT Raised to $22 at Cantor Fitzgerald; 'Preparing for a Momentous 2018'
March 8, 2018 10:42 AM ESTCantor Fitzgerald analyst Elemer Piros raised his price target on Ocular Therapeutix (NASDAQ: OCUL) to $22.00 (from $21.00) while maintaining a Overweight rating, saying the company is preparing for a 'momentous 2018'.
Piros commented, "Ocular hosted a conference call to review its quarterly progress and... More
